It is never too early to call time on an under-performing CEO -...

It is never too early to call time on an under-performing CEO - she has not delivered sustainable value for shareholders in the 15 plus years we have been over paying her.

I think a clinical disappointment now terminate her rather long stay at the trough.

Perhaps Merck can pick up the full tab for her overpriced services for another decade - because I do not think shareholders in Bionomics should.

Her undoubted hard work of talking and globetrotting have done nothing for me and most other long term holders of this stock.

Lots of promise but no real money to show for it.

The only real financial beneficiaries of this company have been the CEO and executives.

Lets get it over with.....................